@article{JTD34211,
author = {Huabin Li and Shi Chen and Lei Cheng and Yinshi Guo and He Lai and Yong Li and Xiaoping Lin and Zheng Liu and Qianhui Qiu and Jie Shao and Li Shi and Man Tian and Chengshuo Wang and Hongtian Wang and Xueyan Wang and Qingyu Wei and Yongxiang Wei and Li Xiang and Qintai Yang and Changqing Zhao and Huanping Zhang and Yuxiang Zhi and Junxiao Gao and Quansheng Li and Juan Liu and Kuiji Wang and Wencheng Zhou and Luo Zhang and Chinese Society of Allergy (CSA)},
title = {Chinese guideline on sublingual immunotherapy for allergic rhinitis and asthma},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {12},
year = {2019},
keywords = {},
abstract = {The present guideline on sublingual immunotherapy (SLIT) for allergic rhinitis (AR) and allergic asthma (AS) has been developed by a panel of experts on behalf of the Chinese Society of Allergy to guide the clinical practice of SLIT in China. The panel included eminent clinical physicians and scientific specialists, who majored in the fields of Otolaryngology, Respirology, Pediatrics, Allergy and Clinical Immunology, and focused their investigations on two common allergic airway diseases (namely AR and AS) in China. During the past few decades, AR and AS have shown increasing prevalence worldwide, and resulted in substantial direct and indirect costs (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/34211}
}